Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05259072 · ClinicalTrials.gov registry record
carDIo-ttranSSfOrm nucLEar Imaging Study
A clinical trial, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- 4
- Enrollment target
NCT05259072: Clinical Trial study, sponsored by Oregon Health and Science University.
NCT05259072 is a clinical trial that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05259072 was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).
Primary Outcome
Percentage of patients in both treatment groups with an improvement in the semi-quantitative visual grade by at least 1 grade from baseline and an improvement in the heart/contralateral ratio by at least 20% from baseline to end of treatment.
Interventions
- DIAGNOSTIC_TEST 99m-technetium pyrophosphate scintigraphy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2023-12-30 |
Why NCT05259072 stopped before completion
NCT05259072 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 99m-technetium pyrophosphate scintigraphy is the first listed.
NCT05259072 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05259072 about?
NCT05259072 is a clinical study titled "carDIo-ttranSSfOrm nucLEar Imaging Study". The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).
What is the current status of trial NCT05259072?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2022-01-19. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT05259072?
The interventions under investigation include: 99m-technetium pyrophosphate scintigraphy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05259072?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI